Showing 1‐10 of 111
Biologics
20 Nov 2024
​​Lonza Announces First GMP Batch Completion at ​Next-Generation Mammalian Manufacturing Facility in Portsmouth (US)
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)   State-of-the-art technology supports Lonza’s next-generation mammalian...
Biologics
12 Nov 2024
Lonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing Suites
The expansion of bioconjugation capabilities will provide additional manufacturing capacity for launch and commercial supply, addressing growing market demand 2,000m2 of...
Biologics
04 Nov 2024
Lonza’s Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza’s commitment to helping...
Biologics
22 Oct 2024
Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC The...
Biologics
15 Oct 2024
Lonza Completes Expansion of New Drug Product Services Facility in Basel (CH)
Expansion adds a new facility to Lonza’s Drug Product Services (DPS) footprint, supporting clinical and commercial projects through additional quality control (QC) and...
Biologics
01 Oct 2024
Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche
The Vacaville site is one of the largest biologics manufacturing facilities in the world Acquisition extends Lonza’s US Biologics footprint with a significant presence on the...
Biologics
26 Sep 2024
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
Agreement builds upon a successful collaboration supporting the manufacture of sabirnetug (ACU193) drug substance (DS) for clinical studies in Alzheimer’s disease Extension to...
Biologics
05 Sep 2024
​​Lonza Completes Expansion of Microbial Manufacturing Facility in Visp (CH) ​
Expansion adds manufacturing capacity for clinical and commercial supply of microbially-produced biologics The facility is now GMP-qualified for manufacturing...
Biologics
15 Aug 2024
UK Government Supports Lonza’s Expansion Plans
Lonza has purchased a plot in Thames Valley Park, with a view to relocating and expanding its primary UK-based Biologics site over the next decade This proposed new site would...
Biologics
04 Apr 2024
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug (ACU193), for clinical development and commercialization, if approved Sabirnetug is the first monoclonal antibody...
1 2 3 4 ... 12 >